ASKA Pharmaceutical Holdings Co.,Ltd. (4886.T)
JPY 2041.0
(-0.34%)
JPY 2041.0
(-0.34%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 62.84 Billion JPY | 3.94% |
| 2022 | 60.46 Billion JPY | 6.81% |
| 2021 | 56.6 Billion JPY | 2.58% |
| 2020 | 55.18 Billion JPY | 5.02% |
| 2019 | 52.54 Billion JPY | 12.5% |
| 2018 | 46.7 Billion JPY | -4.57% |
| 2017 | 48.94 Billion JPY | 0.86% |
| 2016 | 48.52 Billion JPY | 12.29% |
| 2015 | 43.21 Billion JPY | 0.72% |
| 2014 | 42.9 Billion JPY | 8.62% |
| 2013 | 39.5 Billion JPY | -3.57% |
| 2012 | 40.96 Billion JPY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 16.01 Billion JPY | -2.04% |
| 2024 Q1 | 16.35 Billion JPY | 16.64% |
| 2023 FY | 62.84 Billion JPY | 3.94% |
| 2023 Q1 | 16.02 Billion JPY | 21.37% |
| 2023 Q2 | 15.62 Billion JPY | -2.48% |
| 2023 Q3 | 17.17 Billion JPY | 9.93% |
| 2023 Q4 | 14.01 Billion JPY | -18.38% |
| 2022 Q4 | 13.2 Billion JPY | -22.74% |
| 2022 FY | 60.46 Billion JPY | 6.81% |
| 2022 Q3 | 17.08 Billion JPY | 14.65% |
| 2022 Q2 | 14.9 Billion JPY | -2.4% |
| 2022 Q1 | 15.26 Billion JPY | 22.86% |
| 2021 Q3 | 15.7 Billion JPY | 10.14% |
| 2021 FY | 56.6 Billion JPY | 2.58% |
| 2021 Q4 | 12.42 Billion JPY | -20.85% |
| 2021 Q2 | 14.25 Billion JPY | 0.25% |
| 2021 Q1 | 14.22 Billion JPY | 20.2% |
| 2020 Q3 | 15.94 Billion JPY | 16.49% |
| 2020 FY | 55.18 Billion JPY | 5.02% |
| 2020 Q1 | 13.71 Billion JPY | 20.99% |
| 2020 Q2 | 13.68 Billion JPY | -0.18% |
| 2020 Q4 | 11.83 Billion JPY | -25.81% |
| 2019 Q2 | 12.59 Billion JPY | -10.01% |
| 2019 Q3 | 14.62 Billion JPY | 16.15% |
| 2019 Q4 | 11.33 Billion JPY | -22.5% |
| 2019 Q1 | 13.99 Billion JPY | 44.39% |
| 2019 FY | 52.54 Billion JPY | 12.5% |
| 2018 FY | 46.7 Billion JPY | -4.57% |
| 2018 Q4 | 9.69 Billion JPY | -28.43% |
| 2018 Q3 | 13.53 Billion JPY | 26.34% |
| 2018 Q2 | 10.71 Billion JPY | -16.03% |
| 2018 Q1 | 12.76 Billion JPY | 24.73% |
| 2017 FY | 48.94 Billion JPY | 0.86% |
| 2017 Q2 | 12.24 Billion JPY | -4.46% |
| 2017 Q3 | 13.65 Billion JPY | 11.58% |
| 2017 Q4 | 10.23 Billion JPY | -25.1% |
| 2017 Q1 | 12.81 Billion JPY | 15.93% |
| 2016 FY | 48.52 Billion JPY | 12.29% |
| 2016 Q1 | 11.98 Billion JPY | 23.79% |
| 2016 Q2 | 12.32 Billion JPY | 2.85% |
| 2016 Q3 | 13.15 Billion JPY | 6.73% |
| 2016 Q4 | 11.05 Billion JPY | -16.01% |
| 2015 Q4 | 9.68 Billion JPY | -22.07% |
| 2015 Q3 | 12.42 Billion JPY | 19.66% |
| 2015 Q2 | 10.38 Billion JPY | -3.16% |
| 2015 Q1 | 10.72 Billion JPY | 16.69% |
| 2015 FY | 43.21 Billion JPY | 0.72% |
| 2014 Q3 | 10.52 Billion JPY | -17.54% |
| 2014 Q1 | 10.43 Billion JPY | 21.07% |
| 2014 FY | 42.9 Billion JPY | 8.62% |
| 2014 Q4 | 9.18 Billion JPY | -12.68% |
| 2014 Q2 | 12.76 Billion JPY | 22.32% |
| 2013 Q3 | 10.85 Billion JPY | 14.48% |
| 2013 Q1 | 10.54 Billion JPY | 8.14% |
| 2013 Q2 | 9.48 Billion JPY | -10.02% |
| 2013 FY | 39.5 Billion JPY | -3.57% |
| 2013 Q4 | 8.61 Billion JPY | -20.64% |
| 2012 FY | 40.96 Billion JPY | 0.0% |
| 2012 Q4 | 9.74 Billion JPY | -12.0% |
| 2012 Q2 | 9.83 Billion JPY | 0.0% |
| 2012 Q3 | 11.07 Billion JPY | 12.66% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 62.14 Billion JPY | -1.12% |
| Takeda Pharmaceutical Company Limited | 4263.76 Billion JPY | 98.526% |
| Sumitomo Pharma Co., Ltd. | 314.55 Billion JPY | 80.022% |
| Shionogi & Co., Ltd. | 435.08 Billion JPY | 85.556% |
| Wakamoto Pharmaceutical Co.,Ltd. | 7.73 Billion JPY | -712.09% |
| Nippon Shinyaku Co., Ltd. | 148.25 Billion JPY | 57.612% |
| Kaken Pharmaceutical Co., Ltd. | 72.04 Billion JPY | 12.771% |
| Eisai Co., Ltd. | 741.75 Billion JPY | 91.528% |
| Morishita Jintan Co., Ltd. | 12.4 Billion JPY | -406.553% |
| Hisamitsu Pharmaceutical Co., Inc. | 141.7 Billion JPY | 55.653% |
| Mochida Pharmaceutical Co., Ltd. | 102.88 Billion JPY | 38.919% |
| Fuso Pharmaceutical Industries,Ltd. | 55.4 Billion JPY | -13.423% |
| Nippon Chemiphar Co., Ltd. | 30.74 Billion JPY | -104.381% |
| Tsumura & Co. | 150.84 Billion JPY | 58.339% |
| Kissei Pharmaceutical Co., Ltd. | 75.57 Billion JPY | 16.851% |
| Torii Pharmaceutical Co., Ltd. | 54.63 Billion JPY | -15.017% |
| Towa Pharmaceutical Co., Ltd. | 227.93 Billion JPY | 72.429% |
| Fuji Pharma Co., Ltd. | 40.88 Billion JPY | -53.692% |
| Zeria Pharmaceutical Co., Ltd. | 75.72 Billion JPY | 17.012% |
| KYORIN Holdings, Inc. | 119.53 Billion JPY | 47.426% |
| Taiko Pharmaceutical Co.,Ltd. | 5.04 Billion JPY | -1146.885% |
| Daito Pharmaceutical Co.,Ltd. | 46.89 Billion JPY | -34.008% |
| SymBio Pharmaceuticals Limited | 5.58 Billion JPY | -1024.263% |
| MedRx Co., Ltd | 26 Million JPY | -241603.846% |
| Mizuho Medy Co.,Ltd. | 10.98 Billion JPY | -471.834% |
| Solasia Pharma K.K. | 617 Million JPY | -10085.251% |
| Modalis Therapeutics Corporation | - JPY | -Infinity% |
| Sawai Group Holdings Co., Ltd. | 176.86 Billion JPY | 64.468% |
| Cyfuse Biomedical K.K. | 61.11 Million JPY | -102732.504% |
| Toho Holdings Co., Ltd. | 1476.71 Billion JPY | 95.744% |
| Koa Shoji Holdings Co.,Ltd. | 22.13 Billion JPY | -183.919% |